CB4209-CB4211



NAME OF DRUG : CB4209-CB4211

ALSO KNOWN AS : CB4209-CB4211

LABORATORY : CohBar

STATUS AND ADVANCEMENT

Type of drug : MOTS-c peptide analog

Clinical trials advancement : Preclinic

Estimated time to market : 136 months.

LABORATORY ABSTRACT ON THE DRUG

CohBar’s lead clinical development program is based on MOTS-c, an MDP discovered in 2012 by our founders and their academic collaborators. Their research has shown that MOTS-c plays a significant role in the regulation of metabolism. We have developed optimized analogs of the MOTS-c peptide and identified two of these analogs, CB4209 and CB4211, as drug candidates for advancement into IND-enabling activities.

The drug candidates have demonstrated significant therapeutic potential in preclinical models for the treatment of obesity, with additional ongoing studies to determine their therapeutic potential for the treatment of nonalcoholic steatohepatitis (NASH), an advanced form of fatty liver disease, and as an add-on to other drugs for the treatment of Type-2 diabetes.

 

RECENT NEWS ON CB4209-CB4211

2017-02-17 : CohBar, Inc. Announces Positive Results from Preclinical NASH Study of its Lead Drug Candidates

SOME PUBLICATIONS RELATED WITH CB4209-CB4211

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH CB4209-CB4211


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE